COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?

S2-E44.4 – COVID-19 and Fatty Liver: What Impact Will the Delta Variant Have On Clinical Trials?

Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on current and potential impact of the Delta and future variants on clinical trial performance.

Seventeen months ago, Surfing the NASH Tsunami began as a podcast focused on how COVID-19 and the pandemic would affect NASH clinical trials. Some 90 original episodes later, we return to this subject in this conversation. Roger Green asks questions about how COVID-19 has affected clinical trial conduct in the US and other major markets and the rest of the Surfers provide answers about the current and future benefits from what we have learned managing trials in this pandemic. Keep listening to hear some potentially sobering comments on the effect Delta or a possible more potent future variant might have on patient recruitment and assignment. In the end, the four panelists all discuss one point listeners should take away from this conversation.

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"